| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Departments of Urology [H. L., P. M., S. K., Y. X., V. N., N. H. B.], Cell Biology [A. R.], and Pathology [B. K.], New York Hospital-Cornell Medical Center, New York, New York 10021, and the Ludwig Institute for Cancer Research, New York Branch [N. H. B.], New York, New York 10021
Prostate-specific membrane antigen (PSMA), initially defined by monoclonal antibody (mAb) 7E11, is a now well-characterized type 2 integral membrane glycoprotein expressed in a highly restricted manner by prostate epithelial cells. 7E11 has been shown to bind an intracellular epitope of PSMA that, in viable cells, is not available for binding. Herein, we report the initial characterization of the first four reported IgG mAbs that bind the external domain of PSMA. Competitive binding studies indicate these antibodies define two distinct, noncompeting epitopes on the extracellular domain of PSMA. In contrast to 7E11, these mAbs bind to viable LNCaP cells in vitro. In addition, they show strong immunohistochemical reactivity to tissue sections of prostate epithelia, including prostate cancer. These mAbs were also strongly reactive with vascular endothelium within a wide variety of carcinomas (including lung, colon, breast, and others) but not with normal vascular endothelium. These antibodies should prove useful for in vivo targeting to prostate cancer, as well as to the vascular compartment of a wide variety of carcinomas.
1 This work was supported by Grants from CaP CURE, the David H. Koch Charitable Foundation, The Ronald P. and Susan E. Lynch Foundation, the Lawrence and Carol Zicklin Philanthropic Fund, the William T. Morris Foundation, the John E. Wilson Research Fund, the Alissa Beth Bander Memorial Foundation, the Cornell Medical College Urological Oncology Research Fund, and BZL, Inc. N. H. B. is a consultant to BZL, Inc.; N. H. B.'s agreement with BZL is managed by Cornell University in accordance with its conflict of interest policies.
2 To whom requests for reprints should be addressed, at New York Hospital-Cornell Medical Center, Box 23, 525 East 68th Street, New York, NY 10021. E-mail: nhbander@mail.med.cornell.edu.
Received 5/28/97. Accepted 7/16/97.
This article has been cited by other articles:
|
|
 |
|
  S. A. Rajasekaran, J. J. Christiansen, I. Schmid, E. Oshima, K. Sakamoto, J. Weinstein, N. P. Rao, and A. K. Rajasekaran Prostate-specific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability Mol. Cancer Ther., July 1, 2008; 7(7): 2142 - 2151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Pandit-Taskar, J. A. O'Donoghue, M. J. Morris, E. A. Wills, L. H. Schwartz, M. Gonen, H. I. Scher, S. M. Larson, and C. R. Divgi Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using 111In-J591: Lesion Detectability and Dosimetric Projections for 90Y Radioimmunotherapy J. Nucl. Med., July 1, 2008; 49(7): 1066 - 1074. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Balhorn, S. Hok, P. A. Burke, F. C. Lightstone, M. Cosman, A. Zemla, G. Mirick, J. Perkins, A. Natarajan, M. Corzett, et al. Selective High-Affinity Ligand Antibody Mimics for Cancer Diagnosis and Therapy: Initial Application to Lymphoma/Leukemia Clin. Cancer Res., September 15, 2007; 13(18): 5621s - 5628s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Durso, S. Andjelic, J. P. Gardner, D. J. Margitich, G. P. Donovan, R. R. Arrigale, X. Wang, M. F. Maughan, T. L. Talarico, R. A. Olmsted, et al. A Novel Alphavirus Vaccine Encoding Prostate-Specific Membrane Antigen Elicits Potent Cellular and Humoral Immune Responses Clin. Cancer Res., July 1, 2007; 13(13): 3999 - 4008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Morris, N. Pandit-Taskar, C. R. Divgi, S. Bender, J. A. O'Donoghue, A. Nacca, P. Smith-Jones, L. Schwartz, S. Slovin, R. Finn, et al. Phase I Evaluation of J591 as a Vascular Targeting Agent in Progressive Solid Tumors Clin. Cancer Res., May 1, 2007; 13(9): 2707 - 2713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. I. Milowsky, D. M. Nanus, L. Kostakoglu, C. E. Sheehan, S. Vallabhajosula, S. J. Goldsmith, J. S. Ross, and N. H. Bander Vascular Targeted Therapy With Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Advanced Solid Tumors J. Clin. Oncol., February 10, 2007; 25(5): 540 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Christiansen, T. Weimbs, N. Bander, and A. K. Rajasekaran Differing effects of microtubule depolymerizing and stabilizing chemotherapeutic agents on t-SNARE-mediated apical targeting of prostate-specific membrane antigen. Mol. Cancer Ther., October 1, 2006; 5(10): 2468 - 2473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Aggarwal, P. Singh, O. Topaloglu, J. T. Isaacs, and S. R. Denmeade A dimeric Peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. Cancer Res., September 15, 2006; 66(18): 9171 - 9177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Conway, N. Petrovic, Z. Li, W. Heston, D. Wu, and L. H. Shapiro Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol. Cell. Biol., July 1, 2006; 26(14): 5310 - 5324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Ma, C. E. Hopf, A. D. Malewicz, G. P. Donovan, P. D. Senter, W. F. Goeckeler, P. J. Maddon, and W. C. Olson Potent Antitumor Activity of an Auristatin-Conjugated, Fully Human Monoclonal Antibody to Prostate-Specific Membrane Antigen Clin. Cancer Res., April 15, 2006; 12(8): 2591 - 2596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Akiyama, K. A. Mohamedali, R. L. e Silva, S. Kachi, J. Shen, C. Hatara, N. Umeda, S. F. Hackett, S. Aslam, M. Krause, et al. Vascular Targeting of Ocular Neovascularization with a Vascular Endothelial Growth Factor121/Gelonin Chimeric Protein Mol. Pharmacol., December 1, 2005; 68(6): 1543 - 1550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Vallabhajosula, S. J. Goldsmith, L. Kostakoglu, M. I. Milowsky, D. M. Nanus, and N. H. Bander Radioimmunotherapy of Prostate Cancer Using 90Y- and 177Lu-Labeled J591 Monoclonal Antibodies: Effect of Multiple Treatments on Myelotoxicity Clin. Cancer Res., October 1, 2005; 11(19): 7195s - 7200s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. H. Bander, M. I. Milowsky, D. M. Nanus, L. Kostakoglu, S. Vallabhajosula, and S. J. Goldsmith Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer J. Clin. Oncol., July 20, 2005; 23(21): 4591 - 4601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Rajasekaran, G. Anilkumar, and J. J. Christiansen Is prostate-specific membrane antigen a multifunctional protein? Am J Physiol Cell Physiol, May 1, 2005; 288(5): C975 - C981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Vallabhajosula, I. Kuji, K. A. Hamacher, S. Konishi, L. Kostakoglu, P. A. Kothari, M. I. Milowski, D. M. Nanus, N. H. Bander, and S. J. Goldsmith Pharmacokinetics and Biodistribution of 111In- and 177Lu-Labeled J591 Antibody Specific for Prostate-Specific Membrane Antigen: Prediction of 90Y-J591 Radiation Dosimetry Based on 111In or 177Lu? J. Nucl. Med., April 1, 2005; 46(4): 634 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zeng, Q. Wu, H. Li, Q. Wei, Y. Lu, X. Li, F. Wang, F. Zhao, Z. Ding, and Y. Yang Construction of Prostate-Specific Expressed Recombinant Plasmids With High Transcriptional Activity of Prostate-Specific Membrane Antigen (PSMA) Promoter/Enhancer J Androl, March 1, 2005; 26(2): 215 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Emfietzoglou, K. Kostarelos, A. Papakostas, W.-H. Yang, A. Ballangrud, H. Song, and G. Sgouros Liposome-Mediated Radiotherapeutics Within Avascular Tumor Spheroids: Comparative Dosimetry Study for Various Radionuclides, Liposome Systems, and a Targeting Antibody J. Nucl. Med., January 1, 2005; 46(1): 89 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Zitzmann, W. Mier, A. Schad, R. Kinscherf, V. Askoxylakis, S. Kramer, A. Altmann, M. Eisenhut, and U. Haberkorn A New Prostate Carcinoma Binding Peptide (DUP-1) for Tumor Imaging and Therapy Clin. Cancer Res., January 1, 2005; 11(1): 139 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Henry, S. Wen, M. D. Silva, S. Chandra, M. Milton, and P. J. Worland A Prostate-Specific Membrane Antigen-Targeted Monoclonal Antibody-Chemotherapeutic Conjugate Designed for the Treatment of Prostate Cancer Cancer Res., November 1, 2004; 64(21): 7995 - 8001. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Christiansen and A. K. Rajasekaran Biological impediments to monoclonal antibody-based cancer immunotherapy Mol. Cancer Ther., November 1, 2004; 3(11): 1493 - 1501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Milowsky, D. M. Nanus, L. Kostakoglu, S. Vallabhajosula, S. J. Goldsmith, and N. H. Bander Phase I Trial of Yttrium-90--Labeled Anti--Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Androgen-Independent Prostate Cancer J. Clin. Oncol., July 1, 2004; 22(13): 2522 - 2531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Liu, C. Dickinson, J. Shobe, F. Donate, W. Ruf, and T. Edgington A hybrid fibronectin motif protein as an integrin targeting selective tumor vascular thrombogen Mol. Cancer Ther., July 1, 2004; 3(7): 793 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Lupold and R. Rodriguez Disulfide-constrained peptides that bind to the extracellular portion of the prostate-specific membrane antigen Mol. Cancer Ther., May 1, 2004; 3(5): 597 - 603. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Ross, C. E. Sheehan, H. A. G. Fisher, R. P. Kaufman Jr., P. Kaur, K. Gray, I. Webb, G. S. Gray, R. Mosher, and B. V. S. Kallakury Correlation of Primary Tumor Prostate-Specific Membrane Antigen Expression with Disease Recurrence in Prostate Cancer Clin. Cancer Res., December 15, 2003; 9(17): 6357 - 6362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Rajasekaran, G. Anilkumar, E. Oshima, J. U. Bowie, H. Liu, W. Heston, N. H. Bander, and A. K. Rajasekaran A Novel Cytoplasmic Tail MXXXL Motif Mediates the Internalization of Prostate-specific Membrane Antigen Mol. Biol. Cell, December 1, 2003; 14(12): 4835 - 4845. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Schulke, O. A. Varlamova, G. P. Donovan, D. Ma, J. P Gardner, D. M. Morrissey, R. R. Arrigale, C. Zhan, A. J. Chodera, K. G. Surowitz, et al. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy PNAS, October 28, 2003; 100(22): 12590 - 12595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. V. Litvinov, A. M. De Marzo, and J. T. Isaacs Is the Achilles' Heel for Prostate Cancer Therapy a Gain of Function in Androgen Receptor Signaling? J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 2972 - 2982. [Full Text] [PDF]
|
|
|
|
 |
|
 X. Yan, Y. Lin, D. Yang, Y. Shen, M. Yuan, Z. Zhang, P. Li, H. Xia, L. Li, D. Luo, et al. A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth Blood, July 1, 2003; 102(1): 184 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Pinthus, T. Waks, K. Kaufman-Francis, D. G. Schindler, A. Harmelin, H. Kanety, J. Ramon, and Z. Eshhar Immuno-Gene Therapy of Established Prostate Tumors Using Chimeric Receptor-redirected Human Lymphocytes Cancer Res., May 15, 2003; 63(10): 2470 - 2476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Anilkumar, S. A. Rajasekaran, S. Wang, O. Hankinson, N. H. Bander, and A. K. Rajasekaran Prostate-specific Membrane Antigen Association with Filamin A Modulates Its Internalization and NAALADase Activity Cancer Res., May 15, 2003; 63(10): 2645 - 2648. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Smith-Jones, S. Vallabhajosula, V. Navarro, D. Bastidas, S. J. Goldsmith, and N. H. Bander Radiolabeled Monoclonal Antibodies Specific to the Extracellular Domain of Prostate-Specific Membrane Antigen: Preclinical Studies in Nude Mice Bearing LNCaP Human Prostate Tumor J. Nucl. Med., April 1, 2003; 44(4): 610 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Morris and H. I. Scher Clinical Approaches to Osseous Metastases in Prostate Cancer Oncologist, April 1, 2003; 8(2): 161 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Horiguchi, I. Nukaya, K. Okazawa, I. Kawashima, J. Fikes, A. Sette, M. Tachibana, K. Takesako, and M. Murai Screening of HLA-A24-restricted Epitope Peptides from Prostate-specific Membrane Antigen That Induce Specific Antitumor Cytotoxic T Lymphocytes Clin. Cancer Res., December 1, 2002; 8(12): 3885 - 3892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Liu, H. Huang, F. Donate, C. Dickinson, R. Santucci, A. El-Sheikh, R. Vessella, and T. S. Edgington Prostate-specific Membrane Antigen Directed Selective Thrombotic Infarction of Tumors Cancer Res., October 1, 2002; 62(19): 5470 - 5475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Goldenberg Targeted Therapy of Cancer with Radiolabeled Antibodies J. Nucl. Med., May 1, 2002; 43(5): 693 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Ballangrud, W.-H. Yang, D. E. Charlton, M. R. McDevitt, K. A. Hamacher, K. S. Panageas, D. Ma, N. H. Bander, D. A. Scheinberg, and G. Sgouros Response of LNCaP Spheroids after Treatment with an {{alpha}}-Particle Emitter (213Bi)-labeled Anti-Prostate-specific Membrane Antigen Antibody (J591) Cancer Res., March 1, 2001; 61(5): 2008 - 2014. [Abstract] [Full Text]
|
|
|
|
|
|
S. Suzuki, T. Tadakuma, T. Asano, and M. Hayakawa Coexpression of the Partial Androgen Receptor Enhances the Efficacy of Prostate-specific Antigen Promoter-driven Suicide Gene Therapy for Prostate Cancer Cells at Low Testosterone Concentrations Cancer Res., February 1, 2001; 61(4): 1276 - 1279. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. M. Devlin, E.-h. Ling, J. M. Peerson, S. Fernando, R. Clarke, A. D. Smith, and C. H. Halsted Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia Hum. Mol. Genet., November 1, 2000; 9(19): 2837 - 2844. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. McDevitt, E. Barendswaard, D. Ma, L. Lai, M. J. Curcio, G. Sgouros, A. M. Ballangrud, W.-H. Yang, R. D. Finn, V. Pellegrini, et al. An {{alpha}}-Particle Emitting Antibody ([213Bi]J591) for Radioimmunotherapy of Prostate Cancer Cancer Res., November 1, 2000; 60(21): 6095 - 6100. [Abstract] [Full Text]
|
|
|
|
|
|
P. M. Smith-Jones, S. Vallabahajosula, S. J. Goldsmith, V. Navarro, C. J. Hunter, D. Bastidas, and N. H. Bander In Vitro Characterization of Radiolabeled Monoclonal Antibodies Specific for the Extracellular Domain of Prostate-specific Membrane Antigen Cancer Res., September 1, 2000; 60(18): 5237 - 5243. [Abstract] [Full Text]
|
|
|
|
|
|
M. L. Beckett, L. H. Cazares, A. Vlahou, P. F. Schellhammer, and G. L. Wright Jr. Prostate-specific Membrane Antigen Levels in Sera from Healthy Men and Patients with Benign Prostate Hyperplasia or Prostate Cancer Clin. Cancer Res., December 1, 1999; 5(12): 4034 - 4040. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Chang, D. S. O'Keefe, D. J. Bacich, V. E. Reuter, W. D. W. Heston, and P. B. Gaudin Prostate-specific Membrane Antigen Is Produced in Tumor-associated Neovasculature Clin. Cancer Res., October 1, 1999; 5(10): 2674 - 2681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Chang, V. E. Reuter, W. D. W. Heston, N. H. Bander, L. S. Grauer, and P. B. Gaudin Five Different Anti-Prostate-specific Membrane Antigen (PSMA) Antibodies Confirm PSMA Expression in Tumor-associated Neovasculature Cancer Res., July 1, 1999; 59(13): 3192 - 3198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Reiter, Z. Gu, T. Watabe, G. Thomas, K. Szigeti, E. Davis, M. Wahl, S. Nisitani, J. Yamashiro, M. M. Le Beau, et al. Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer PNAS, February 17, 1998; 95(4): 1735 - 1740. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
